Real-world efficacy, safety, and usability of a microvolume eyedrop delivery device in glaucoma: prospective randomized crossover trial.
Jennifer S Steger, José E Capó-Aponte, Alexandra Papp...
https://pubmed.ncbi.nlm.nih.gov/41185150/Actively Recruiting
Led by 59th Medical Wing · Updated on 2023-05-06
30
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and effectiveness of using Nanodropper-mediated microdrops of eye pressure-lowering medications compared to standard full-volume eyedrops in patients with primary open-angle glaucoma POAG and ocular hypertension OHTN. This randomized, single-masked crossover trial aims to see if the smaller drops delivered by Nanodropper affect intraocular pressure IOP differently than regular drops over time. Participants will use two different delivery methods during the study. One group starts with Nanodropper microdrops daily for three months followed by a three-month period using standard eyedrops, while the other group begins with standard drops and then switches to Nanodropper. Patients will have safety checks one month after starting Nanodropper use and clinical assessments at three and six months. During the study, participants will have their eye pressure measured to track changes from baseline to six months. Additional tests include visual acuity, retinal nerve fiber layer thickness, and visual field assessments. Patients will also complete surveys about side effects and ease of use. The total participation lasts six months with several follow-up visits to monitor safety and effectiveness.
CONDITIONS
Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial
J
Jose E Capo-Aponte, OD, PhD
J
Jennifer Steger, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
59th Medical Wing
Lead Sponsor
Nanodropper, Inc.
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Nanodropper (microvolume delivery) | Regular Dropper (conventional device) |
|---|---|---|
| What is it? | A microvolume eyedrop adapter delivering roughly one-fifth the volume per drop compared to a regular dropper. | Conventional eyedrop device delivering standard full-volume drops without modification. |
| Role in trial | Compared directly with conventional dropper in a crossover trial for glaucoma and ocular hypertension management. | Served as active comparator for conventional eyedrop delivery within the same participant group. |
| Primary use | To administer glaucoma or ocular hypertension eyedrop medications using much smaller drop volume, potentially improving dosing precision and conserving medication. | To deliver glaucoma or ocular hypertension eyedrop medications using conventional drop volume. |
| How it is given or performed | Participants use the Nanodropper adapter attached to medication bottle, delivering smaller drops as prescribed. | Participants administer eyedrop medications as usual, directly from the standard bottle without an adapter. |
| Evidence status | Randomized crossover trial and additional peer-reviewed publication support real-world usability and efficacy for stable glaucoma and ocular hypertension patients. | Conventional dropper use for glaucoma eyedrop administration is well-established as current practice in published real-world device comparison literature. |
| Important limitations | Trial population limited to stable glaucoma or ocular hypertension on ≤2 medications; possible device usability concerns in broader patient groups. Results for those with advanced or unstable disease not yet established. | Conventional dropper may waste medication due to larger drops and is not designed for precise microvolume dosing; broader device usability issues are reported in literature. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants use either Nanodropper or regular dropper with their intraocular pressure-lowering eyedrops for 3 months, then crossover to the other delivery system for another 3 months.
Visits at 1 month, 3 months, 4 months, and 6 months for safety and clinical assessments
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
OTHER
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Jennifer S Steger, José E Capó-Aponte, Alexandra Papp...
https://pubmed.ncbi.nlm.nih.gov/41185150/59th Medical Wing
Lead Sponsor
Nanodropper, Inc.
Collaborating Sponsor